blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2025248

EP2025248 - Cachexia prevention supplement [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.12.2009
Database last updated on 03.09.2024
Most recent event   Tooltip18.12.2009Application deemed to be withdrawnpublished on 20.01.2010  [2010/03]
Applicant(s)For all designated states
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg v.d.H. / DE
[2009/08]
Inventor(s)01 / Schneid, Christina, Dr.
Hindenburgstrasse 35
55118 Mainz / DE
 [2009/08]
Representative(s)Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Strasse 4
80335 München / DE
[N/P]
Former [2009/08]TER MEER - STEINMEISTER & PARTNER GbR
Mauerkircherstrasse 45
81679 München / DE
Application number, filing date07015027.131.07.2007
[2009/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2025248
Date:18.02.2009
Language:EN
[2009/08]
Search report(s)(Supplementary) European search report - dispatched on:EP20.05.2008
ClassificationIPC:A23L1/29, A23L1/30, A61K31/20
[2009/08]
CPC:
A61K31/202 (EP,US); A23L33/105 (EP,US); A23L33/12 (EP,US);
A23L33/15 (EP,US); A23L33/175 (EP,US); A61K31/20 (EP,US);
A61P1/14 (EP); A61P3/04 (EP); A61P7/00 (EP);
A23V2002/00 (EP,US) (-)
C-Set:
A23V2002/00, A23V2250/187, A23V2250/2132, A23V2250/0654, A23V2250/0628, A23V2250/0626, A23V2250/062, A23V2250/211, A23V2250/70, A23V2250/708 (EP,US);
A23V2002/00, A23V2250/187, A23V2250/214, A23V2250/0654, A23V2250/0628, A23V2250/0626, A23V2250/062, A23V2250/211, A23V2250/70, A23V2250/708 (US,EP)
Designated contracting states(deleted) [2009/43]
Former [2009/08]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Zubehör zur Verhinderung von Abmagerungen[2009/08]
English:Cachexia prevention supplement[2009/08]
French:Supplément pour la prévention de l'émaciation[2009/08]
Examination procedure19.08.2009Application deemed to be withdrawn, date of legal effect  [2010/03]
02.09.2009Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2010/03]
Fees paidPenalty fee
Additional fee for renewal fee
31.07.200903   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XD]WO0007607  (KOSBAB JOHN V [US]) [XD] 1-15 * examples 3-18; table 2 *;
 [X]US6649195  (GORSEK WAYNE F [US]) [X] 1,5-8,10 * table 1 *;
 [X]WO2004105517  (DSM IP ASSETS BV [NL], et al) [X] 1,5,7,8,10,16* example 4 *;
 [X]US2005032757  (CHO SUK H [US]) [X] 1,5,8,10,11 * paragraph [0096] - paragraph [0099]; examples 3-16; claims 1-12 *;
 [X]WO2005110124  (ABBOTT LAB [US]) [X] 1-3,6,10-15 * page 2, line 26 - line 28 * * page 14, line 4 - line 10; claims 1,13,19-23; tables 1-9 *;
 [X]DE202005012984U  (W & B PHARMAMARKEN GMBH [DE]) [X] 1,2,4-8,10,11 * the whole document *;
 [X]DE202006014588U  (ORTHOMOL PHARMAZEUTISCHE VERTR [DE]) [X] 1,5-8,10,11 * paragraph [0008] - paragraph [0009] * * paragraph [0019] - paragraph [0036]; claims 1-17 *;
 [X]DE202007000949U  (VOGEL LUKAS [DE], et al) [X] 1,2,5-8,10,11 * paragraph [0018] - paragraph [0024]; claims 1-4 *;
 [E]WO2007149590  (PROCTER & GAMBLE [US], et al) [E] 1,5,10 * example 2 *;
 [X]  - MANTOVANI G ET AL, "CANCER-RELATED ANOREXIA/CACHEXIA SYNDROME AND OXIDATIVE STRESS: AN INNOVATIVE APPROACH BEYOND CURRENT TREATMENT", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, PHILADELPHIA, PA, (20041001), vol. 13, no. 10, ISSN 1055-9965, pages 1651 - 1659, XP008065515 [X] 1,5,8,10-15 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.